Dyvon Plus 20gm .05 gm + .005 gm/100 gm

Ointment

Pack Size : 1 Cream x 1 Packate

Generics : Betamethasone 0.05% + Calcipotriol 0.005% topical

Manufacturer : Square Pharmaceuticals Ltd.

Best Price * TK 381.14

* Delivery will be done in Dhaka city only.

Alternative Product

Oinment Dyvon Plus - .05 gm Square Pharmaceuticals Ltd.

Tk 381.14

Oinment Dyvon - 20 gm Square Pharmaceuticals Ltd.

Tk 381.14

Solutions Dyvon Plus 25ml 50 mg + 5 mg/100 gm Square Pharmaceuticals Ltd.

Tk 552.00

More Information About - Dyvon Plus 20gm .05 gm + .005 gm/100 gm

Description

Generic Name

Betamethasone 0.05% + Calcipotriol 0.005% topical

Precaution

Not to be used on face, axillae or groin. Not to be applied to more than 30% of the body surface area. Monitor serum calcium levels; treatment should be temporarily discontinued if levels exceeded normal range. Prolonged usage or concurrent use with occlusive dressings may increase absorption of the drugs into the systemic circulation. Regular monitoring for evidence of hypothalamic-pituitary-adrenal axis suppression is recommended. Efficacy and safety have not been evaluated in patients with severe renal or hepatic impairment. Pregnancy and lactation.

Indication

Psoriasis

Contra Indication

Known or suspected disorders of calcium metabolism. Patients with erythrodermic, exfoliative and pustular psoriasis.

Dose

N/A

Side Effect

Pruritus, rash, burning sensation of the skin, dry skin, erythema, rash, dermatitis, eczema, photosensitivity and hypersensitivity reactions. May aggravate psoriasis.

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Betamethasone dipropionate is a synthetic corticosteroid that has anti-inflammatory, antipruritic and vasoconstrictive properties. Calcipotriol is a vitamin D analogue. It may induce differentiation and suppress proliferation of keratinocytes.

Interaction

N/A

Pregnancy Category Note

Pregnancy The limited data on use in pregnant women are not sufficient to evaluate associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes; observational studies suggest an increased risk of having low birth weight infants with the maternal use of potent or very potent topical corticosteroids; advise pregnant women that therapy may increase potential risk of having a low birth weight infant and to use product on smallest area of skin and for shortest duration possible; in animal reproduction studies Lactation There is no information regarding presence of topically administered calcipotriene and betamethasone dipropionate in human milk, effects on breastfed infant, or on milk production; not known whether topically administered calcipotriene or corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk; developmental and health benefits of breastfeeding should be considered along with mother?s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition; to minimize potential exposure to breastfed infant via breast milk, use drug on smallest area of skin and for shortest duration possible while breastfeeding; advise breastfeeding women not to apply drug directly to nipple and areola to avoid direct infant exposure

Adult Dose

Adult: Topical : >18 yr: Apply once daily up to 4 wk. Max: 100 g/wk.

Child Dose

N/A

Renal Dose

N/A

Administration

N/A

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.